Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Robbins LLP Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders
04:52pm, Friday, 07'th May 2021
SAN DIEGO & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $CCXI--Shareholder rights law firm Robbins LLP announces that a purchaser of ChemoCentryx, Inc. (NASDAQ: CCXI) filed a class action complaint aga
RADNOR, Pa.--(BUSINESS WIRE)---- $CCXI #classaction--Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.
Here's why ChemoCentryx plunged 60% in the stock market on Friday
01:50pm, Friday, 07'th May 2021
ChemoCentryx Inc (NASDAQ: CCXI) tanked roughly 60% in the stock market on Friday as approval for its drug for an autoimmune disease hung in the balance. ChemoCentryx is seeking FDA approval for Avacop
Why ChemoCentryx Stock Is Cratering Again Today
12:22pm, Friday, 07'th May 2021
Investors aren't optimistic after an FDA advisory committee vote for avacopan.
Los Angeles, California--(Newsfile Corp. - May 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ChemoCentryx, Inc. ("C
Why ChemoCentryx Shares Are Plunging Today
10:41am, Friday, 07'th May 2021
ChemoCentryx (NASDAQ: CCXI) shares are trading lower following a vote from the FDA panel on whether the efficacy data support approval on its Avacopan in ANCA-Associated vasculitis. The vote on wheth
Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges
10:17am, Friday, 07'th May 2021
Yesterday, the FDA's Arthritis Advisory Committee panelists went through cloudy data while complaining about the design of the Phase 3 trial for ChemoCentryx Inc's (NASDAQ: CCXI) avacopan. After go
FDA advisory committee votes 10-8 in favor of ChemoCentryx's experimental drug; stock is down
10:14am, Friday, 07'th May 2021
Shares of ChemoCentryx Inc. tumbled 61.7% in trading on Friday, the day after a Food and Drug Administration advisory committee voted 10-8 that the benefits of the company's experimental autoimmune dr
Boston, Massachusetts--(Newsfile Corp. - May 7, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that has filed a class action lawsuit on behalf of
CCXI INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
09:35am, Friday, 07'th May 2021
SAN FRANCISCO, May 7, 2021 /PRNewswire/ -- Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pendi
Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate
06:47am, Friday, 07'th May 2021
The FDA's Arthritis Advisory Committee voted 10 for and 8 against the approval of ChemoCentryx Inc's (NASDAQ: CCXI) investigational drug avacopan as a treatment for adults with a rare and serious
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
11:37pm, Thursday, 06'th May 2021
SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (
NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 6, 2021 to file
LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CCXI--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc.
The Law Offices of Frank R. Cruz Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors
05:17pm, Thursday, 06'th May 2021
LOS ANGELES--(BUSINESS WIRE)---- $CCXI #investors--The Law Offices of Frank R. Cruz Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors
